De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Insmed Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Insmed is gedaald met een gemiddeld jaarlijks percentage van -24.9%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.7%. De inkomsten zijn groeide met een gemiddeld percentage van 21.8% per jaar.

Belangrijke informatie

-24.9%

Groei van de winst

-12.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	21.8%
Rendement op eigen vermogen	-2,067.8%
Nettomarge	-244.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

Dec 18

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Jul 28

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jul 01

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Apr 18

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Feb 23

Insmed inks financing agreements to raise $500M

Oct 19

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24

Opbrengsten en kosten

Hoe Insmed geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:INSM Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	329	-803	380	514
31 Mar 24	315	-747	358	564
31 Dec 23	305	-750	345	571
30 Sep 23	281	-724	328	559
30 Jun 23	269	-696	313	549
31 Mar 23	257	-547	289	441
31 Dec 22	245	-482	266	398
30 Sep 22	242	-434	257	349
30 Jun 22	221	-416	242	320
31 Mar 22	201	-438	239	296
31 Dec 21	188	-435	234	273
30 Sep 21	174	-424	225	264
30 Jun 21	171	-375	211	235
31 Mar 21	168	-319	204	221
31 Dec 20	164	-294	204	181
30 Sep 20	169	-245	198	90
30 Jun 20	164	-242	205	111
31 Mar 20	151	-247	207	79
31 Dec 19	136	-254	211	132
30 Sep 19	101	-293	215	202
30 Jun 19	62	-320	206	155
31 Mar 19	32	-330	190	151
31 Dec 18	10	-324	168	145
30 Sep 18	0	-298	146	55
30 Jun 18	0	-256	119	49
31 Mar 18	0	-224	98	45
31 Dec 17	0	-193	79	110
30 Sep 17	0	-196	60	37
30 Jun 17	0	-188	56	38
31 Mar 17	0	-180	52	36
31 Dec 16	0	-176	51	35
30 Sep 16	0	-139	51	34
30 Jun 16	0	-132	49	30
31 Mar 16	0	-124	46	27
31 Dec 15	0	-118	43	23
30 Sep 15	0	-105	39	24
30 Jun 15	0	-98	36	24
31 Mar 15	0	-92	34	18
31 Dec 14	0	-79	31	23
30 Sep 14	0	-78	29	-3
30 Jun 14	0	-71	25	19
31 Mar 14	0	-57	25	16

Kwaliteitswinsten: INSM is momenteel verliesgevend.

Groeiende winstmarge: INSM is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: INSM is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 24.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van INSM over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: INSM is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: INSM heeft een negatief Return on Equity ( -2067.84% ), omdat het momenteel verliesgevend is.

Insmed Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Recent updates

Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up

Chief Medical Officer notifies of intention to sell stock

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Chief People Strategy Officer recently sold US$686k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Insider notifies of intention to sell stock

Is Insmed (NASDAQ:INSM) A Risky Investment?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 8.7% to US$82.63

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Price target increased by 7.0% to US$73.44

Chief Medical Officer exercised options and sold US$768k worth of stock

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Chief Financial Officer notifies of intention to sell stock

Price target increased by 25% to US$56.56

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

Insmed Incorporated Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

New major risk - Share price stability

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

President recently sold US$566k worth of stock

President notifies of intention to sell stock

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed inks financing agreements to raise $500M

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022